Italia markets close in 1 hour 13 minutes

FTSE MIB
33.540,06
-167,15(-0,50%)
Dow Jones
38.976,21
-135,95(-0,35%)
Nasdaq
17.765,08
+47,43(+0,27%)
Nikkei 225
39.667,07
+493,92(+1,26%)
Petrolio
81,00
+0,17(+0,21%)
Bitcoin EUR
57.970,78
+564,89(+0,98%)

NBIX Nov 2024 170.000 call

OPR - OPR Prezzo differito. Valuta in USD.

Aggiungi a watchlist

5,30

0,00

(0,00%)

In data: 11:17AM EDT. Mercato aperto.

GlobeNewswire
Sosei Heptares’ partner Neurocrine Biosciences Initiates Phase 1 Clinical Study Evaluating Effects of NBI-1117570 in Healthy Adults
NBI-1117570 is an investigational, oral, muscarinic M1/M4 selective dual agonist discovered by Sosei Heptares that may have the potential to treat neurological and neuropsychiatric conditionsNBI-1117570 is the second compound to advance into clinical development from a portfolio of selective muscarinic receptor agonists licensed by Sosei Heptares to Neurocrine following NBI-1117568, an oral, selective muscarinic M4 receptor agonist, which is in Phase 2 clinical trials as an investigational treat